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Changes in Lipoprotein-Associated Phospholipase A2 Activity Predict
Coronary Events and Partly Account for the Treatment Effect
of Pravastatin: Results From the Long-term Intervention
with Pravastatin in Ischemic Disease Study
Harvey D. White, DSc;* John Simes, MD;* Ralph A. H. Stewart, MD; Stefan Blankenberg, MD; Elizabeth H. Barnes, MStat;
Ian C. Marschner, PhD; Peter Thompson, MD; Malcolm West, MD; Tanja Zeller, PhD; David M. Colquhoun, MD; Paul Nestel, MD;
Anthony C. Keech, MD; David R. Sullivan, MD; David Hunt, MD; Andrew Tonkin, MD; for the LIPID Study Investigators
Background-—Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are associated with coronary heart disease (CHD) in
healthy individuals and in patients who have had ischemic events.
Methods and Results-—The Long-term Interventionwith Pravastatin in Ischemic Disease (LIPID) study randomized 9014 patients with
cholesterol levels of 4.0 to 7.0 mmol/L to placebo or pravastatin 3 to 36 months after myocardial infarction or unstable angina and
showed a reduction in CHD and total mortality. We assessed the value of baseline and change in Lp-PLA2 activity to predict outcomes
over a 6-year follow-up, the effect of pravastatin on Lp-PLA2 levels, and whether pravastatin treatment effect was related to Lp-PLA2
activity change. Lp-PLA2 wasmeasured at randomization and 1 year, and levels were grouped as quartiles. The prespeciﬁed end point
was CHD death or nonfatal myocardial infarction. Baseline Lp-PLA2 activity was positively associated with CHD events (P<0.001) but
not after adjustment for 23 baseline factors (P=0.66). In 6518 patients who were event free at 1 year, change in Lp-PLA2 was a
signiﬁcant independent predictor of subsequent CHD events after adjustment for these risk factors, including LDL cholesterol and LDL
cholesterol changes (P<0.001). Pravastatin reduced Lp-PLA2 by 16% compared with placebo (P<0.001). After adjustment for Lp-PLA2
change, the pravastatin treatment effect was reduced from 23% to 10% (P=0.26), with 59% of the treatment effect accounted for by
changes in Lp-PLA2. Similar reductions in treatment effect were seen after adjustment for LDL cholesterol change.
Conclusion-—Reduction in Lp-PLA2 activity during the ﬁrst year was a highly signiﬁcant predictor of CHD events, independent of
change in LDL cholesterol, and may account for over half of the beneﬁts of pravastatin in the LIPID study. ( J Am Heart Assoc.
2013;2:e000360 doi: 10.1161/JAHA.113.000360)
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P roducts of the enzyme lipoprotein-associated phospho-lipase A2 (Lp-PLA2) are found in plaques and are
proinﬂammatory and proapoptotic.1 Lp-PLA2 is also a marker
of vulnerable plaques.2,3 Elevated plasma Lp-PLA2 levels are
associated with increased coronary heart disease (CHD) risk
in both healthy individuals and patients who have already had
coronary events.4
The Long-term Intervention with Pravastatin in Ischaemic
Disease (LIPID) study was a large double-blind, placebo-
controlled study of pravastatin in stable CHD patients.5
During a mean 6.0-year follow-up, there were signiﬁcant
reductions in the primary end point of death from CHD, all-
cause mortality, and other prespeciﬁed cardiovascular end
points, including the composite of nonfatal myocardial
infarction (MI) or CHD death. There was a reduction in death
from CHD death by 24% (P<0.001) and overall mortality by
22% (P<0.001). Nonfatal MI or death due to CHD was reduced
by 24%.
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Reduction in LDL cholesterol (LDL-C) is thought to be the
major mechanism by which statins reduce risk. It is possible
that other mechanisms are also important. Statins have been
shown to reduce Lp-PLA2 levels by up to 33%,
6,7,15,16 and
therefore some of the beneﬁts of pravastatin could be
explained by this effect. We therefore assessed in a prespec-
iﬁed analysis of the LIPID study data the predictive value of
baseline and changes in Lp-PLA2 for major coronary events
(CHD death or nonfatal MI), the effect of pravastatin on Lp-
PLA2 levels, and the extent to which pravastatin treatment
effect might be explained by effects on Lp-PLA2.
Methods
Study Design and Patients
The design and major results of the LIPID study have been
described in detail previously.5 A total of 9014 patients aged
31 to 75 years (7498 men, 1516 women), with an MI or
hospital discharge diagnosis of unstable angina 3 to
36 months previously, were enrolled on the study if their
plasma total cholesterol was 4.0 to 7.0 mmol/L (155 to
271 mg/dL), fasting triglycerides were <445 mg/dL
(<5.0 mmol/L), and they satisﬁed other broad inclusion and
exclusion criteria. After informed consent and an 8-week
placebo run-in phase to assess compliance, patients were
randomly allocated to receive pravastatin 40 mg daily or
matching placebo. Patients were otherwise treated with
standard therapies.
The primary prespeciﬁed outcome for substudies was a
composite of CHD death and nonfatal MI. MI was diagnosed
by the presence of at least 2 new pathologic Q waves on the
electrocardiogram or 2 of the following 3 criteria: ≥15 min-
utes of ischemic chest pain, evolutionary ST-T wave changes,
or elevation of the serum level of creatine kinase or its MB
isoenzyme to at least twice the upper limit of normal. All
deaths and MIs were reviewed by an Outcomes Assessment
Committee whose members had no knowledge of the
patient’s treatment assignment.
The trial and biomarker analyses were conceived, man-
aged, and analyzed independently of the sponsor.
Laboratory Methods and Biomarkers
Blood was drawn from consenting participants at baseline
before treatment allocation after a 12-hour fast into EDTA
tubes, and plasma was stored at 70°C. Biomarkers including
Lp-PLA2 were analyzed using baseline samples from 87% of
patients (n=7863) and 86% (n=6657) of patients alive at
1 year.
Lp-PLA2 activity was measured in a research-use auto-
mated enzyme assay system (CAM Assay; DiaDexus Inc), run
on the Abbott Architect c8000 analyzer, using a colorimetric
PAF analog substrate that is converted on hydrolysis by the
phospholipase enzyme. The assay is calibrated to a highly
puriﬁed recombinant Lp-PLA2 standard. Intra-assay coefﬁcient
of variation (CV) was 1.2%, and interassay CV was 3.8%. All
assay measurements were performed by laboratory personnel
who were blinded to the study samples regarding treatment
assignment and outcomes.
Fasting serum lipids (total cholesterol, HDL cholesterol,
and triglycerides) were measured in a central laboratory at
Flinders Medical Centre, Adelaide, South Australia, a World
Health Organization reference center. LDL cholesterol was
calculated using the Friedewald formula.8
Statistics
Analyses were prespeciﬁed in a biomarker protocol. Base-
line Lp-PLA2 activity and changes to 1 year were grouped
as quartiles. Hazard ratios (HRs) and 95% CIs were
estimated using Cox proportional-hazards regression mod-
els. Analyses were adjusted for sex, pravastatin treatment,
and 22 other traditional risk factors. The primary end point
for biomarker analyses was a composite of CHD death and
nonfatal MI. Secondary end points included major
cardiovascular disease (CVD) outcomes (a composite of
CVD death, MI, and stroke) and total CVD outcomes (a
composite of major CVD events, unstable angina, and
coronary revascularization).
The relationship between Lp-PLA2 activity and CVD
outcomes was assessed using a prespeciﬁed time to event
model adjusted for sex, randomized treatment, prior stroke,
diabetes mellitus, current smoking, hypertension, fasting
glucose, total cholesterol, apolipoprotein B, apolipoprotein
A1, HDL cholesterol, triglycerides, age, nature of prior acute
coronary syndromes, timing of coronary revascularization,
systolic blood pressure, atrial ﬁbrillation, estimated glomer-
ular ﬁltration rate, body mass index, dyspnea class, angina
grade, white blood cell count, peripheral vascular disease, and
use of aspirin at baseline.
The relationship between changes in Lp-PLA2 activity
from baseline to 1 year and subsequent CVD events was
assessed in a landmark analysis using Cox regression in a
model that incorporated the standard risk factors previously
indicated as well as baseline Lp-PLA2 activity. We also
performed backward selection for a landmark model looking
at events from 1 year adjusted for baseline brain natriuretic
peptide, baseline cystatin C, baseline D-dimer, baseline
troponin I, baseline Lp-PLA2 activity, and change in these
same biomarkers.
The extent to which the pravastatin effect on subsequent
CVD events was accounted for by changes in Lp-PLA2 activity
and changes in LDL-C was assessed by estimating the
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relative risk reduction from pravastatin before and after
adjustment for these changes as continuous variables in
these Cox regression models.9 A sensitivity analysis of
treatment effect accounted for by changes in Lp-PLA2 activity
and LDL-C used change in these variables grouped in
quartiles.
Results
Of the 9014 patients randomized in LIPID, 7863 patients had
baseline measurement of Lp-PLA2 levels and formed the
cohort for this study (Figure 1). The baseline characteristics
of patients included and of those not included in this analysis
are shown in Table 1.
Baseline characteristics of the patients divided into the
quartiles (<229, 229 to 261, 261 to 294, >294 nmoL/min
per milliliter) of Lp-PLA2 activity are shown in Table 2. Lp-PLA2
activity was signiﬁcantly lower in females (Figure 2) and with
lower LDL-C, lower triglycerides, or higher HDL cholesterol
levels. There were higher associations with a history of
multiple MIs, higher LIPID risk score,10 higher WBC, cystatin
C, and lower estimated glomerular ﬁltration rate. Lp-PLA2
activity was not associated with high-sensitivity C-reactive
protein or troponin I.
Relationship Between Lp-PLA2 and Clinical Events
Higher baseline Lp-PLA2 activity was associated with an
increased risk of CHD events, major CVD events, total CVD
events, CHD death, and all-cause mortality signiﬁcant (each
P≤0.01). After adjustment for all baseline factors, there was
no longer a signiﬁcant association between Lp-PLA2 activity
and clinical events with the exception of CHD death (P=0.05)
(Figure 3).
Effect of Pravastatin on Lp-PLA2 Levels and CVD
Events
Lp-PLA2 activity levels were reduced by 16% (262 nmoL/
min per milliliter versus 218 nmoL/min per milliliter) in the
pravastatin group at 12 months while levels decreased by
0.4% in the placebo group (P<0.001) (Figures 4 and 5).
Figures 6 and 7 show the relationship between levels of
Lp-PLA2 levels and on treatment LDL-C at baseline and
changes to year 1. Effects of pravastatin on clinical events
by each quartile of Lp-PLA2 activity are shown in Table 3.
Pravastatin resulted in a signiﬁcant reduction in CHD
events, CVD events, CHD death, and all-cause mortality
with no signiﬁcant variation in treatment effect according
to baseline Lp-PLA2 activity. The numbers needed to treat
to prevent 1 event were lower in patients with higher
Lp-PLA2 activity, but there was no signiﬁcant trend in the
effect of pravastatin across the quartiles of baseline Lp-
PLA2 activity.
Relationship Between Change in Lp-PLA2 Activity
and Events
Figure 8 shows the association of change of Lp-PLA2 over
1 year with subsequent CVD events. A larger decrease in
Lp-PLA2 was associated with fewer CHD events (P<0.002),
major CVD events (P=0.003), and total CVD events (P=0.001)
after adjustment for baseline factors. In a landmark model
looking at events after 1 year and adjusting for baseline brain
natriuretic peptide, baseline cystatin C, baseline D-dimer,
baseline troponin I, baseline Lp-PLA2 activity, and change in
these same biomarkers, there was still a strong association
with change in Lp-PLA2 activity and CHD events (P<0.001)
(Table 4). Further models were ﬁtted to examine the strength
of the association between change in Lp-PLA2 activity and
events after year 1. These models were not prespeciﬁed but
were included as a sensitivity analysis. They showed that
when baseline and change in LDL-C were included in the
model and/or when baseline and change in Lp-PLA2 and
LDL-C were ﬁtted as continuous variables rather than
quartiles, the strong association between change in Lp-PLA2
and CHD events was maintained, while change in LDL-C was
not a predictor of outcomes (data not shown).
Extent of Pravastatin Treatment Effect Explained
by Change in Lp-PLA2
Figure 9 shows the effect of pravastatin versus placebo on
CVD events before and after adjustment for changes in Lp-
PLA2 activity and LDL-C. Pravastatin was associated with a
23% reduction in CHD events after adjustment for all baseline
risk factors (P<0.001). After adjustment for change in LDL-C,Figure 1. Consort diagram for patient ﬂow.
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Table 1. Baseline Characteristics of Patients in the Biomarker Analysis vs Others
Patients With All Biomarker Readings at Baseline All Other Patients
P Value*7863 (100%) 1151 (100%)
Pravastatin, No. (%) 3941 (50) 571 (50)
Age at randomization, y, median (IQR) 62.0 (55.0 to 67.0) 61.0 (54.0 to 67.0) <0.001
Age ≥65 y, No. (%) 3109 (40) 405 (35) <0.01
Female, No. (%) 1333 (17) 183 (16) 0.37
Baseline health
Months from QE, median (IQR) 13.9 (7.9 to 25.0) 12.8 (7.6 to 24.0) 0.03
Current smoker, No. (%) 735 (9) 134 (12) 0.01
Hypertension, No. (%) 3291 (42) 467 (41) 0.41
Diabetes, No. (%) 676 (9) 106 (9) 0.49
Obese, No. (%) 1397 (18) 214 (19) 0.50
Stroke, No. (%) 322 (4) 47 (4) 0.99
Atrial fibrillation, No. (%) 110 (1) 13 (1) 0.46
Systolic BP, mean (SD), mm Hg 134 (19) 133 (18) 0.11
Diastolic BP, mean (SD), mm Hg 81 (11) 80 (11) 0.64
Dyspnea NYHA Class >1, No. (%) 761 (10) 97 (8) 0.18
Angina CCS Grade >0, No. (%) 2927 (37) 401 (35) 0.12
Baseline lipids
Total cholesterol, mean (SD), nmol/L 5.7 (0.8) 5.6 (0.8) 0.03
Total cholesterol ≥5.5 mmol/L, No. (%) 4495 (57) 639 (56) 0.29
LDL-C, mean (SD), nmol/L 3.9 (0.7) 3.8 (0.7) <0.01
LDL-C ≥3.5 mmol/L, No. (%) 5513 (70) 780 (68) 0.11
HDL-C, mean (SD), nmol/L 1.0 (0.2) 1.0 (0.2) 0.84
HDL-C ≥1 mmol/L, No. (%) 2936 (37) 422 (37) 0.67
Triglyceride, median (IQR), nmol/L 1.6 (1.2 to 2.2) 1.6 (1.2 to 2.2) 0.39
Total cholesterol:HDL-C, mean (SD), nmol/L 6.2 (1.5) 6.2 (1.5) 0.37
eGFR, median (IQR), mLs/min 69 (60 to 80) 70 (60 to 81) 0.56
WBC, median (IQR) 9109 7.0 (6.0 to 8.2) 7.1 (6.0 to 8.3) 0.30
Previous coronary revascularization
No revascularization, No. (%) 4610 (59) 712 (62) 0.03
PCI only, No. (%) 870 (11) 118 (10) —
CABG only, No. (%) 2141 (27) 295 (26) —
PCI and CABG, No. (%) 242 (3) 26 (2) —
Qualifying Event
No MI, No. (%) 2843 (36) 417 (36) 0.90
Single MI, No. (%) 4115 (52) 604 (52) —
Multiple MI, No. (%) 905 (12) 130 (11) —
Medications
Aspirin, No. (%) 6501 (83) 901 (78) <0.001
ACE inhibitors, No. (%) 1254 (16) 179 (16) 0.73
b-Blocker, No. (%) 3691 (47) 538 (47) 0.90
Calcium antagonist, No. (%) 2688 (34) 424 (37) 0.08
LIPID risk score, mean (SD)10 5.8 (3.5) 6.0 (3.5) 0.26
No. (%) is presented unless otherwise stated. ACE indicates angiotensin-converting enzyme; BP, blood pressure; CABG, coronary artery bypass graft surgery; CCS, Canadian Cardiovascular
Society; eGFR, estimated glomerular ﬁltration rate; HDL-C, HDL cholesterol; IQR, interquartile range; LDL-C, LDL cholesterol; LIPID, Long-term Intervention with Pravastatin in Ischaemic
Disease; MI, myocardial infarction, NYHA, New York Heart Association; PCI, percutaneous coronary intervention; WBC, white blood cell count.
*P-values for continuous variables are from a linear model, and for categorical variables are from an ordinal or logistic regression.
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Table 2. Baseline Risk Factors by Lp-PLA2 Activity Categories
Lp-PLA2 Activity
≤229 nmol/min per
milliliter
Lp-PLA2 Activity
229 to 261 nmol/min per
milliliter
Lp-PLA2 Activity
261 to 294 nmol/min per
milliliter
Lp-PLA2 Activity
>294 nmol/min per
milliliter
P Value
Trend*1970 1962 1965 1966
Lp-PLA2 activity, mean (SD), nmol/min
per milliliter
199.4 (25.4) 245.8 (9.1) 276.8 (9.4) 326.0 (29.5)
Age at randomization, median (IQR), y 63.0 (56.0 to 68.0) 63.0 (56.0 to 68.0) 62.0 (55.0 to 67.0) 62.0 (55.0 to 67.0) <0.01
Age ≥65 y, No. (%) 798 (41) 819 (42) 733 (37) 759 (39) 0.06
Female, No. (%) 658 (33) 364 (19) 195 (10) 116 (6) <0.001
Allocated pravastatin, No. (%) 990 (50) 996 (51) 981 (50) 974 (50) 0.57
Baseline health
Months from QE, median (IQR) 13.4 (7.5 to 24.9) 13.5 (7.6 to 24.6) 14.3 (8.0 to 25.2) 14.5 (8.3 to 25.3) 0.05
Current smoker, No. (%) 156 (8) 181 (9) 183 (9) 215 (11) <0.01
Hypertension, No. (%) 877 (45) 818 (42) 801 (41) 795 (40) <0.01
Diabetes mellitus, No. (%) 201 (10) 167 (9) 152 (8) 156 (8) <0.01
Obese, No. (%) 357 (18) 354 (18) 340 (17) 346 (18) 0.56
Previous stroke, No. (%) 83 (4) 74 (4) 78 (4) 87 (4) 0.68
Atrial fibrillation, No. (%) 21 (1) 20 (1) 30 (2) 39 (2) <0.01
Systolic BP, mean (SD), mm Hg 135 (19) 135 (19) 134 (19) 134 (20) 0.11
Diastolic BP, mean (SD), mm Hg 80 (11) 81 (11) 81 (11) 81 (11) 0.32
Dyspnea, No. (%) NYHA Class >1, No.
(%)
205 (10) 171 (9) 163 (8) 222 (11) 0.40
Angina CCS Grade >0, No. (%) 727 (37) 681 (35) 711 (36) 808 (41) <0.01
Baseline lipids
Total cholesterol, mean (SD), mmol/L 5.5 (0.9) 5.6 (0.8) 5.7 (0.8) 5.8 (0.8) <0.001
LDL-C, mean (SD) 3.6 (0.7) 3.9 (0.7) 4.0 (0.7) 4.1 (0.7) <0.001
HDL-C, mean (SD) 1.1 (0.3) 1.0 (0.2) 0.9 (0.2) 0.8 (0.2) <0.001
Triglycerides, median (IQR) 1.4 (1.1 to 2.0) 1.5 (1.1 to 2.1) 1.6 (1.2 to 2.2) 1.7 (1.3 to 2.3) <0.001
Total cholesterol:HDL-C, mean (SD) 5.3 (1.4) 6.0 (1.3) 6.4 (1.3) 7.1 (1.5) <0.001
Previous coronary revascularization
No revascularization, No. (%) 1197 (61) 1145 (58) 1145 (58) 1123 (57) <0.001
PCI only, No. (%) 259 (13) 221 (11) 230 (12) 160 (8) —
CABG only, No. (%) 453 (23) 531 (27) 532 (27) 625 (32) —
PCI and CABG, No. (%) 61 (3) 65 (3) 58 (3) 58 (3) —
Qualifying Event
No MI, No. (%) 762 (39) 703 (36) 687 (35) 691 (35) <0.001
Single MI, No. (%) 1025 (52) 1042 (53) 1047 (53) 1001 (51) —
Multiple MI, No. (%) 183 (9) 217 (11) 231 (12) 274 (14) —
Medications
Aspirin, No. (%) 1611 (82) 1631 (83) 1666 (85) 1593 (81) 0.78
ACE inhibitors, No. (%) 310 (16) 297 (15) 297 (15) 350 (18) 0.08
b-Blocker, No. (%) 928 (47) 896 (46) 961 (49) 906 (46) 0.92
Calcium antagonist, No. (%) 701 (36) 664 (34) 636 (32) 687 (35) 0.52
Continued
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the estimated decrease in CHD events by pravastatin was
reduced to 13%, accounting for 44% of the treatment effect.
After adjustment for change in Lp-PLA2 activity, the estimated
decrease in CHD events by pravastatin was reduced to 10%,
with 59% of the treatment effect accounted for by change in
Lp-PLA2 activity.
When the expanded endpoint of total CVD events was
used, the relative risk reduction with pravastatin was reduced
after adjustment for both changes in Lp-PLA2 and LDL-C, to
0% (P=0.98). When these same analyses were conducted
using quartiles of change, only change in Lp-PLA2 activity, and
not change in LDL-C, accounted for the pravastatin treatment
effect.
Discussion
This study is the largest and the longest study of CHD patients
to evaluate the relationship of Lp-PLA2 activity to CHD
outcomes. Baseline Lp-PLA2 activity levels were not related to
outcomes except for CHD death. Lp-PLA2 activity levels at
randomization were reduced after 1 year on pravastatin by
16%. Similar relative effects of pravastatin were observed
within each subgroup deﬁned by baseline Lp-PLA2 quartiles
but with greater absolute beneﬁt among those with higher
baseline levels. While baseline Lp-PLA2 activity was not
independently associated with outcomes after adjustment for
all other risk factors, reduction in Lp-PLA2 activity from
randomization to 1 year was a signiﬁcant independent
predictor of CHD events even after adjustment for treatment
and 23 baseline risk factors. This remained highly signiﬁcant
even after adjustment for change in brain natriuretic peptide,
tropinin I, and LDL-C.
The major novel ﬁnding of this study is that change in Lp-
PLA2 levels accounted for at least as much of the pravastatin
treatment effect on reducing CHD death and MI as did LDL-C
reduction. While the changes in Lp-PLA2 and LDL-C are
related, this observation suggests that statins could reduce
Table 2. Continued
Lp-PLA2 Activity
≤229 nmol/min per
milliliter
Lp-PLA2 Activity
229 to 261 nmol/min per
milliliter
Lp-PLA2 Activity
261 to 294 nmol/min per
milliliter
Lp-PLA2 Activity
>294 nmol/min per
milliliter
P Value
Trend*1970 1962 1965 1966
LIPID risk score,10 mean (SD) 4.9 (3.4) 5.7 (3.4) 6.0 (3.4) 6.7 (3.5) <0.001
Baseline biomarker levels
eGFR, median (IQR), mL/min 70 (60 to 81) 70 (61 to 80) 70 (61 to 80) 69 (59 to 80) <0.001
WBC, median (IQR), 9109 6.9 (5.9 to 8.1) 6.9 (5.9 to 8.1) 7.1 (6.0 to 8.2) 7.2 (6.1 to 8.5) <0.001
BNP, median (IQR), pg/mL 23.9 (10.0 to 51.9) 23.3 (9.7 to 50.1) 23.1 (10.0 to 49.2) 23.6 (9.6 to 52.1) 0.03
Troponin I, median (IQR), ng/mL 0.011 (0.006 to 0.021) 0.010 (0.006 to 0.019) 0.010 (0.006 to 0.021) 0.011 (0.006 to 0.021) 0.55
CRP, median (IQR), mg/L 2.5 (1.2 to 5.0) 2.4 (1.2 to 4.9) 2.4 (1.2 to 4.6) 2.5 (1.3 to 4.8) 0.15
Cystatin C, median (IQR), mg/L 0.78 (0.70 to 0.89) 0.80 (0.72 to 0.91) 0.81 (0.73 to 0.93) 0.85 (0.75 to 0.97) <0.001
D-dimer, median (IQR), ng/L 168 (109 to 266) 167 (109 to 270) 174 (112 to 276) 183 (117 to 278) 0.63
LP(a), median (IQR), mg/L 13.5 (6.4 to 39.6) 13.7 (6.5 to 43.8) 14.3 (6.7 to 46.3) 14.1 (6.8 to 46.7) <0.01
Mid regional proadrenomedullin,
median (IQR), nmol/L
0.47 (0.37 to 0.57) 0.47 (0.38 to 0.58) 0.48 (0.39 to 0.57) 0.48 (0.39 to 0.59) 0.02
No. (%) is presented unless otherwise stated. BNP indicates brain natriuretic peptide; BP, blood pressure; CABG, coronary artery bypass graft surgery; CCS, Canadian Cardiovascular
Society; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; HDL-C, HDL cholesterol; IQR, interquartile range; LDL-C, LDL lipoprotein cholesterol; LIPID, Long-term
Intervention with Pravastatin in Ischaemic Disease; LP, lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2; MI, myocardial infarction, NYHA, New York Heart Association;
PCI, percutaneous coronary intervention; WBC, white blood cell count.
*P-values for trend for continuous variables are from generalized linear models and, for categorical variables, are from an ordinal or logistic regression.
Figure 2. Distribution of lipoprotein-associated phospholipase A2
(Lp-PLA2) activity levels. Baseline Lp-PLA2 activity by sex, P<0.0001.
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CHD risk in part by decreasing Lp-PLA2 activity.
4,11 The CIs
around estimates of proportion of treatment effect explained
are wide and do not enable meaningful comparison between
the estimates for LDL-C and Lp-PLA2, which limits the
conclusions that can be made from these results. However,
all statistical models showed that change in Lp-PLA2 was at
least as strongly associated with CHD events as was change
in LDL-C.
Lp-PLA2 is produced by blood-borne inﬂammatory cells
(monocytes, macrophages, T cells, mast cells) and is
predominantly carried by LDL.12 Pathological studies in
animals have shown increased staining for Lp-PLA2 in thin
cap ﬁbroatheroma and ruptured vulnerable plaques.2 Higher
plasma levels of Lp-PLA2 have also been shown to be
associated with coronary artery endothelial dysfunction in
humans,13 and coronary production of Lp-PLA2 is correlated
with the degree of plaque as assessed by intravascular
ultrasound.14
In an analysis of 79 000 patients from 32 studies, Lp-PLA2
activity was shown to be higher in men than in women and to
be positively associated with LDL-C and inversely correlated
with HDL cholesterol.4 Higher plasma levels of Lp-PLA2 were
associated with cardiovascular events, including mortality, MI,
and stroke.
Statins have been shown to reduce Lp-PLA2 activity
levels.6,7,15,16 In the PRavastatin OR atorVastatin Evaluation
and Infection Therapy (PROVE-IT) study, treatment with
atorvastatin 80 mg/d was associated with a 20% reduction
in Lp-PLA2 activity at 30 days (P<0.001), whereas Lp-PLA2
rose 3.6% with pravastatin 40 mg/d (P<0.001).7 There was
no placebo control group in this study. It is possible that as
Lp-PLA2 levels fall after acute coronary syndromes, as part of
an acute-phase reaction, that the effect of pravastatin on
decreasing Lp-PLA2 activity may have been obscured by levels
increasing back toward the baseline levels that existed before
the acute coronary syndrome. In a study of subjects free of
Figure 3. Baseline Lp-PLA2 activity and prediction of CVD events. HR and 95% CI are adjusted for baseline variables: treatment, sex, stroke,
diabetes, smoking, hypertension, total cholesterol, apolipoprotein B and A1, HDL-C, age, nature of prior ACS, timing of coronary revascularization,
SBP, atrial ﬁbrillation, eGFR, BMI, dyspnea class, angina grade, WBC, peripheral vascular disease, triglycerides, fasting glucose and aspirin at
baseline. ACS indicates acute coronary syndromes; BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; eGFR,
estimated glomerular ﬁltration rate; HDL-C, HDL cholesterol; HR, hazard ratio; Lp-PLA2, lipoprotein-associated phospholipase A2; MI, myocardial
infarction; SBP, systolic blood pressure; WBC, white blood cell count.
Figure 4. Distribution of lipoprotein-associated phospholipase A2
(Lp-PLA2) activity levels. Lp-PLA2 activity at 1 year by randomized
treatment, P<0.001.
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CVD, Lp-PLA2 levels were reduced 12.3% with pravastatin
40 mg at 12 months compared with placebo.15
In the Heart Protection Study (HPS), simvastatin reduced
Lp-PLA2 activity by 25%, but the effects of simvastatin on
vascular outcomes did not vary according to Lp-PLA2 levels.
6
In the Justiﬁcation for the Use of statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, Lp-
PLA2 activity was associated with cardiovascular risk.
16
Rosuvastatin reduced Lp-PLA2 activity by 33.2% (P<0.0001),
and Lp-PLA2 no longer predicted risk in patients treated with
rosuvastatin. The mechanisms for inhibition of Lp-PLA2
activity by statins are not well deﬁned. However, simvastatin
has been shown to reduce Lp-PLA2 expression and activity in
lipopolysaccharide-stimulated human myocyte-derived mac-
rophages through inhibition of the mevalonate–geranylgeranyl
pyrophosphate–RhoA–p38 mitogen-activated protein kinase
pathway.17
In the current study, it is not known if pravastatin also
reduced the Lp-PLA2 activity in plaques. If this occurred, the
complexity of coronary lesions may have been reduced and
potentially progression of the necrotic core may have been
halted with stabilization of coronary atheromatous plaques.
This could explain the reduction in CHD events that was
observed. The results from the Cholesterol Treatment Trialists
(CTT) overview, which did not use a landmark analysis, are
consistent with most of the effects of statins being correlated
with the size of the magnitude of reduction in LDL-C change,
but this can still allow for additional mechanisms to contrib-
ute.18 We have previously shown that 50%9 of the treatment
effect of pravastatin in the LIPID study was explained by
reduction in LDL-C.
Darapladib, a potent reversible inhibitor of Lp-PLA2, has
been shown in diabetic, hypercholesterolemic pigs to reduce
the inﬂammatory product of Lp-PLA2 lysophosphatidylcholine
content of coronary plaque and to reduce macrophage
inﬁltration into the arterial wall and to reduce the necrotic
core of plaque.19 In humans, darapladib has been shown to
lower Lp-PLA2 activity by 60% and, in the Integrated Biomarker
and Imaging Study-2 (IBIS 2) trial, to reduce the secondary end
point of the necrotic core of coronary artery plaque.20 Ongoing
randomized trials of darapladib will establish whether lowering
of Lp-PLA2 activity may lower the risk of cardiovascular death,
MI, and stroke after MI21 and after an acute coronary syndrome.22
Limitations
There are several limitations of this study. These ﬁndings are
from a clinical study and the randomized patients may not be
Figure 6. Lp-PLA2 activity vs LDL-C at baseline. LDL-C indicates
LDL cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2.
Figure 7. Change in Lp-PLA2 activity vs change in LDL-C. LDL-C
indicates LDL cholesterol; Lp-PLA2, lipoprotein-associated phospho-
lipase A2.
Figure 5. Distribution of lipoprotein-associated phospholipase A2
(Lp-PLA2) activity levels. Change in Lp-PLA2 activity from baseline to
1 year by randomized treatment, P<0.001.
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Table 3. Effect of Pravastatin Treatment on Clinical Events by Each Quartile of Baseline Lp-PLA2 Activity
End Point
Lp-PLA2 Activity
(nmol/min per milliliter)
Placebo
(5-y rate, %)
Pravastatin
(5-y rate, %)
Hazard Ratio
(95% CI)
NNT
(Based on Common HR)
Interaction
P Value
Trend
CHD events (CHD death or
nonfatal MI)
≤229 10.9 9.1 0.83 (0.64, 1.07) 45 0.36
229 to 261 11.7 11.3 0.86 (0.68, 1.09 42
261 to 294 12.6 9.5 0.73 (0.57, 0.93) 39
>294 16.1 12.3 0.74 (0.59, 0.92) 31
Major CVD events (CVD death,
nonfatal MI, or stroke)
≤229 14.0 12.1 0.83 (0.66, 1.04) 35 0.27
229 to 261 14.3 13.6 0.89 (0.72, 1.10) 34
261 to 294 16.9 11.6 0.66 (0.53, 0.83) 29
>294 19.7 15.5 0.75 (0.62, 0.91) 25
Total CVD events (major CVD,
unstable angina, or
revascularization)
≤229 32.9 30.8 0.88 (0.76, 1.02) 25 0.63
229 to 261 34.8 30.0 0.86 (0.74, 0.99) 24
261 to 294 35.4 31.0 0.83 (0.72, 0.96) 24
>294 40.3 35.5 0.84 (0.74, 0.97) 22
CHD death ≤229 5.1 3.5 0.73 (0.49, 1.08) 87 0.84
229 to 261 5.8 6.0 0.84 (0.60, 1.16) 77
261 to 294 6.4 4.3 0.68 (0.47, 0.96) 70
>294 8.4 7.2 0.81 (0.61, 1.08) 54
All-cause mortality ≤229 9.1 7.2 0.78 (0.59, 1.02) 49 0.92
229 to 261 10.4 9.8 0.81 (0.63, 1.03) 43
261 to 294 10.7 7.7 0.64 (0.49, 0.84) 42
>294 11.8 10.7 0.83 (0.65, 1.04) 38
CHD indicates coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio; Lp-PLA2, lipoprotein-associated phospholipase A2;MI,myocardial infarction, NNT, number needed to treat.
Figure 8. Quartiles of change in Lp-PLA2 activity and prediction of CVD events. HR and 95% CI are adjusted for baseline variables: treatment,
sex, stroke, diabetes, smoking, hypertension, total cholesterol, apolipoprotein B and A1, HDL-C, age, nature of prior ACS, timing of coronary
revascularization, SBP, atrial ﬁbrillation, eGFR, BMI, dyspnea class, angina grade, WBC, peripheral vascular disease, triglycerides, fasting glucose,
aspirin at baseline and change in LDL. ACS indicates acute coronary syndromes; BMI, body mass index; CHD, coronary heart disease; CVD,
cardiovascular disease; eGFR, estimated glomerular ﬁltration rate; HDL-C, HDL cholesterol; HR, hazard ratio; Lp-PLA2, lipoprotein-associated
phospholipase A2; MI, myocardial infarction; SBP, systolic blood pressure; WBC, white blood cell count.
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fully representative of patients seen in clinical practice.
Biomarker data were not available in some patients. However,
the patients excluded compared with the patients included
were younger, more likely to be male, and more likely to not
have a history of hypertension and to not have had coronary
revascularization.
There are limitations in using a landmark analysis to
determine what proportion of treatment effect can be
explained by change in a particular biomarker. Measurement
error in the landmark analyses would tend to underestimate
the associations we found. Estimates of the proportion of
treatment effect accounted for by change in a biomarker are
inherently imprecise.23 Nonetheless, the observation that
changes in Lp-PLA2 accounted for at least as much of the
pravastatin effect as LDL-C reduction is informative and
provides support for the hypothesis that part of the pravast-
atin effect is mediated through Lp-PLA2 change.
Conclusion
Higher baseline levels of Lp-PLA2 activity signiﬁcantly pre-
dicted an increased risk of CVD events including CHD death
and MI, total CVD events, and all-cause mortality, but not in
multivariate analyses except for CHD death. Pravastatin
signiﬁcantly reduced Lp-PLA2 activity over 1 year by 16%
compared with placebo. Similar relative effects of pravastatin
were observed within each subgroup deﬁned by baseline Lp-
PLA2 quartiles and greater absolute beneﬁt was found in
those with higher baseline levels.
Reduction in Lp-PLA2 strongly predicts a reduction in
subsequent CHD events after adjustment for treatment, 23
baseline risk factors, and other biomarkers and for changes in
other biomarkers and for reduction in LDL-C.
Changes in Lp-PLA2 appears to account for much of the
pravastatin treatment effect (more than half) and appear to be
at least as important as changes in LDL-C. Some of the effect
of Lp-PLA2 change (and LDL-C change) may be surrogates for
each other, but both appear to account for more of the
treatment effect than change in LDL-C alone. This novel
Table 4. Coronary Events After 1-Year with Adjustment for
Baseline Factors, Baseline Biomarkers and Change in
Biomarkers
Variables Level HR (95% CI)
P Value
Trend
Baseline
Lp-PLA2
activity
≤229.142 1 0.04
229.142 to 261.028 1.14 (0.91, 1.42)
261.028 to 293.767 1.11 (0.89, 1.39)
>293.767 1.27 (1.01, 1.58)
Change in
Lp-PLA2
activity
≤46.6057 1 <0.001
46.6057 to 19.8282 1.16 (0.92, 1.47)
19.8282 to 2.8565 1.29 (0.99, 1.69)
>2.8565 1.61 (1.23, 2.11)
Lp-PLA2 indicates lipoprotein-associated phospholipase A2; HR, hazard ratio.
Baseline Factors: Treatment, sex, stroke, diabetes, smoking, hypertension, total
cholesterol, apolipoprotein B and A1, HDL cholesterol, age, nature of prior acute
coronary syndromes, timing of coronary revascularization, systolic blood pressure, atrial
ﬁbrillation, estimated glomerular ﬁltration rate, body mass index, dyspnea class, angina
grade, white blood cell count, peripheral vascular disease, triglycerides, fasting glucose,
and aspirin at baseline.
Baseline Biomarkers: Baseline brain natriuretic peptide, baseline cystatin C, baseline D-
dimer, baseline troponin I, and baseline Lp-PLA2.
Change in Biomarkers: Change in brain natriuretic peptide, troponin I, and Lp-PLA2
activity.
Figure 9. Effect of pravastatin on events after adjustment for changes in Lp-PLA2 activity and LDL cholesterol (LDL-C).9 Baseline and change in
LDL-C and Lp-PLA2 activity are expressed as continuous variables. CHD indicates coronary heart disease; CVD, cardiovascular disease; HR, hazard
ratio; Lp-PLA2, lipoprotein-associated phospholipase A2; MI, myocardial infarction; RRR, relative risk reduction.
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ﬁnding requires validation in other studies, especially in
ongoing trials. These results raise the possibility of additional
mechanisms of statin effects on CVD event reduction and also
provide a rationale for ongoing trials testing inhibitors of
Lp-PLA2 activity.
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